Govt notifies NIAB as central drugs lab for COVID vaccines

Published On 2021-08-19 06:30 GMT   |   Update On 2021-08-19 12:47 GMT
Advertisement

Hyderabad: In a move that will speed up the testing and lot release of Covid-19 vaccines, the National Institute of Animal Biotechnology (NIAB), Hyderabad, has been notified as a Central Drugs Laboratory (CDL) by the Union ministry of health & family welfare (MoHFW).

The move will bring much respite to Hyderabad-based vaccine makers such as Bharat Biotech, Biological E and Indian Immunologicals Ltd, which are engaged in the manufacture Covid-19 vaccines, as all the lots had to be first sent to CDL Kasauli for testing and release.
Advertisement
The notification came after the Central Drugs Standard Control Organisation (CDSCO) furnished a draft notification to MoHFW for notifying NIAB, Hyderabad, as a CDL laboratory.
Apart from NIAB, Hyderabad, the name of National Centre for Cell Sciences (NCCS) at Pune too was recommended.



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News